Compare Moderna, Inc. (MRNA) vs Toyota Motor Corp (TM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs Toyota Motor Corp — how do they compare? Moderna, Inc. trades at $196.72 (market cap $78.44B), while Toyota Motor Corp trades at $184.37 (market cap $216.99B). The key difference: Toyota Motor Corp is far larger — about 2.8× Moderna, Inc.'s market cap, and Toyota Motor Corp pays a 3.43% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Moderna, Inc. for 59 Days and Toyota Motor Corp for 116 Days on average.
| MRNA | TM | |
|---|---|---|
Market Cap | $78.44B | $216.99B |
Volume | 14,597,511 | 314,929 |
Sector | Health | Consumer Cyclical |
52-Week High | $203.46 | $248.29 |
52-Week Low | $22.36 | $166.50 |
Typical Hold Time | 59 Days | 116 Days |
Enterprise Value | $74.59B | $410.32B |
Dividend Yield | — | 3.43% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $197.00, up 5.09% today, with a bullish technical signal supported by moving averages. Recent inclusion in the Nasdaq-100 index has driven positive momentum, though the stock faces valuation concerns after a 500% rally in 2026. Financially, revenue has declined from $18.9B in 2022 to $1.92B in 2025, with net losses widening to -$2.82B. Earnings have consistently beaten expectations, but profitability metrics remain negative.
Outlook: Near-term upside may be capped by high valuations and profit-taking pressure, but long-term growth potential exists in the oncology pipeline. Key risks include sustained revenue declines, competitive threats, and reliance on pipeline success. Analysts are mixed, with a consensus price target of $115.70 suggesting caution despite bullish technicals.
Toyota Motor trades at $182.91, down 1.43% with bearish technical signals but attractive valuation metrics including P/E of 8.22 and P/B of 0.92. The company reported strong Q2 2026 earnings beat with EPS of $7.57 versus $4.68 expected, though revenue growth has moderated to 6.5% year-over-year. Recent news highlights Toyota's expanding electrified vehicle lineup and U.S. market share gains, while facing production challenges from Thailand floods and China sales weakness.
Toyota presents a value opportunity with solid profitability (8.63% net margin) and consistent earnings beats, but faces near-term headwinds from production disruptions and competitive pressures. Analyst consensus leans cautious with 62.5% hold ratings, suggesting the stock may consolidate near current levels despite attractive valuation multiples.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About Toyota Motor Corp
Founded in 1937, Toyota is one of the world's largest automakers with 10.38 million units sold at retail in fiscal 2022 across its light vehicle brands. Brands include Toyota, Lexus, Daihatsu, and truck maker Hino.
Read more on TM →
